| Neuroendocrine neoplasms (NENs) are rare tumors originating from peptide-producing neurons and neuroendocrine cells, demonstrating neuroendocrine differentiation and expression of neuroendocrine markers. In recent years, integrated molecular probes in nuclear medicine have rapidly advanced the clinical understanding and treatment of NENs, providing significant clinical value. Radiolabeled molecular probes have shown distinct advantages in the diagnosis of NENs, enabling whole-body specific imaging for early diagnosis, clinical staging, monitoring of recurrence and metastasis, and follow-up assessments. The widespread application of this technology offers more precise treatment plans for patients. Furthermore, therapeutic radiolabeled molecular probes have demonstrated notable clinical efficacy in the treatment of NENs, introducing new therapeutic options for patients. This review comprehensively explores the applications and progress of various novel nuclear medicine molecular probes in the diagnosis and treatment of NENs. |
